OBJECTIVE: Phospholamban ablation or ectopic expression of SERCA1a in the heart results in significant increases in cardiac contractile parameters. The aim of the present study was to determine whether a combination of these two genetic manipulations may lead to further augmentation of cardiac function. METHODS: Transgenic mice with cardiac specific overexpression of SERCA1a were mated with phospholamban deficient mice to generate a model with SERCA1a overexpression in the phospholamban null background (SERCA1(OE)/PLB(KO)). The cardiac phenotype was characterized using quantitative immunoblotting, sarcoplasmic reticulum calcium uptake and single myocyte mechanics and calcium kinetics. RESULTS: Quantitative immunoblotting revealed an increase of 1.8-fold in total SERCA level, while SERCA2 was decreased to 50% of wild types. Isolated myocytes indicated increases in the maximal rates of contraction by 195 and 125%, the maximal rates of relaxation by 200 and 124%, while the time for 80% decay of the Ca(2+)-transient was decreased to 43 and 75%, in SERCA1(OE)/PLB(KO) hearts, compared to SERCA1a overexpressors and phospholamban knockouts, respectively. These mechanical alterations reflected parallel alterations in V(max) and EC(50) for Ca(2+) of the sarcoplasmic reticulum Ca(2+) transport system. Furthermore, there were no significant cardiac histological or pathological alterations, and the myocyte contractile parameters remained enhanced, up to 12 months of age. CONCLUSIONS: These findings suggest that a combination of SERCA1a overexpression and phospholamban ablation results in further enhancement of myocyte contractility over each individual alteration.
OBJECTIVE: Phospholamban ablation or ectopic expression of SERCA1a in the heart results in significant increases in cardiac contractile parameters. The aim of the present study was to determine whether a combination of these two genetic manipulations may lead to further augmentation of cardiac function. METHODS:Transgenic mice with cardiac specific overexpression of SERCA1a were mated with phospholamban deficient mice to generate a model with SERCA1a overexpression in the phospholamban null background (SERCA1(OE)/PLB(KO)). The cardiac phenotype was characterized using quantitative immunoblotting, sarcoplasmic reticulum calcium uptake and single myocyte mechanics and calcium kinetics. RESULTS: Quantitative immunoblotting revealed an increase of 1.8-fold in total SERCA level, while SERCA2 was decreased to 50% of wild types. Isolated myocytes indicated increases in the maximal rates of contraction by 195 and 125%, the maximal rates of relaxation by 200 and 124%, while the time for 80% decay of the Ca(2+)-transient was decreased to 43 and 75%, in SERCA1(OE)/PLB(KO) hearts, compared to SERCA1a overexpressors and phospholamban knockouts, respectively. These mechanical alterations reflected parallel alterations in V(max) and EC(50) for Ca(2+) of the sarcoplasmic reticulum Ca(2+) transport system. Furthermore, there were no significant cardiac histological or pathological alterations, and the myocyte contractile parameters remained enhanced, up to 12 months of age. CONCLUSIONS: These findings suggest that a combination of SERCA1a overexpression and phospholamban ablation results in further enhancement of myocyte contractility over each individual alteration.
Authors: F C Howarth; M A Qureshi; Z Hassan; D Isaev; K Parekh; A John; M Oz; H Raza; E Adeghate; T E Adrian Journal: Mol Cell Biochem Date: 2011-10-19 Impact factor: 3.396
Authors: Lucia Brunello; Jessica L Slabaugh; Przemyslaw B Radwanski; Hsiang-Ting Ho; Andriy E Belevych; Qing Lou; Haiyan Chen; Carlo Napolitano; Francesco Lodola; Silvia G Priori; Vadim V Fedorov; Pompeo Volpe; Michael Fill; Paul M L Janssen; Sándor Györke Journal: Proc Natl Acad Sci U S A Date: 2013-06-03 Impact factor: 11.205
Authors: Qiujing Song; Albrecht G Schmidt; Harvey S Hahn; Andrew N Carr; Beate Frank; Luke Pater; Mike Gerst; Karen Young; Brian D Hoit; Bradley K McConnell; Kobra Haghighi; Christine E Seidman; Jonathan G Seidman; Gerald W Dorn; Evangelia G Kranias Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Anuradha Kalyanasundaram; Véronique A Lacombe; Andriy E Belevych; Lucia Brunello; Cynthia A Carnes; Paul M L Janssen; Bjørn C Knollmann; Muthu Periasamy; Sandor Gyørke Journal: Cardiovasc Res Date: 2012-11-06 Impact factor: 10.787
Authors: Vivian Capilla-Gonzalez; Sara Gil-Perotin; Antonio Ferragud; Luis Bonet-Ponce; Juan Jose Canales; Jose Manuel Garcia-Verdugo Journal: PLoS One Date: 2012-01-04 Impact factor: 3.240